We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+48.4%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$858M
AUM Growth
+$272M
(+47%)
Cap. Flow
+$61M
Cap. Flow
% of AUM
7.11%
Top 10 Holdings %
Top 10 Hldgs %
51.45%
Holding
74
New
10
Increased
22
Reduced
15
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$23M |
| 2 |
Krystal Biotech
KRYS
|
+$22.3M |
| 3 |
Glaukos
GKOS
|
+$20.9M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$19.4M |
| 5 |
Genmab
GMAB
|
+$16.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VAPO
Vapotherm, Inc. Common Stock
VAPO
|
+$19.5M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$15.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$11M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$10.2M |
| 5 |
AtriCure
ATRC
|
+$9.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.12% |
| 2 | Communication Services | 3.8% |
| 3 | Energy | 0.29% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
KORU Medical Systems
KRMD
$189M
| $67.6M | 7.88% |
7,532,150
+293,558
| +4% | +$2.97M |
|
|
OXFD
2
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $60.1M | 7.01% |
4,625,202
+575,162
| +14% | +$6.91M |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| $59.1M | 6.89% |
1,668,740
-348,363
| -17% | -$10.2M |
|
|
SPNE
4
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $53.5M | 6.24% |
5,112,910
+623,357
| +14% | +$6.37M |
|
5
CareDx
CDNA
$2.26B
| $47.2M | 5.5% |
1,332,938
+247,186
| +23% | +$7.03M |
|
6
Halozyme
HALO
$9.79B
| $39.1M | 4.56% |
1,458,545
-172,046
| -11% | -$3.88M |
|
|
MODN
7
DELISTED
MODEL N, INC.
MODN
| $32.6M | 3.8% |
938,288
+12,367
| +1% | +$360K |
|
8
Insmed
INSM
$21.4B
| $28.2M | 3.29% |
1,024,438
+4,701
| +0.5% | +$111K |
|
9
Tandem Diabetes Care
TNDM
$1.34B
| $27.7M | 3.23% |
280,350
-5,841
| -2% | -$466K |
|
|
YMAB
10
DELISTED
Y-mAbs Therapeutics
YMAB
| $26.2M | 3.06% |
+607,621
| New | +$23M |
|
11
Teva Pharmaceuticals
TEVA
$40.8B
| $25.7M | 2.99% |
2,084,103
+240,857
| +13% | +$2.72M |
|
|
12
Glaukos
GKOS
$9.83B
| $25M | 2.91% |
651,021
+560,456
| +619% | +$20.9M |
|
|
13
AtriCure
ATRC
$1.92B
| $24.3M | 2.83% |
539,762
-211,056
| -28% | -$9.19M |
|
|
14
Genmab
GMAB
$17.7B
| $20.2M | 2.36% |
+596,374
| New | +$16.3M |
|
|
PFNX
15
DELISTED
Pfenex Inc.
PFNX
| $19.6M | 2.29% |
2,348,799
+9,128
| +0.4% | +$68.3K |
|
|
16
Krystal Biotech
KRYS
$10.1B
| $19.2M | 2.24% |
+464,179
| New | +$22.3M |
|
17
NeoGenomics
NEO
$1.96B
| $19M | 2.21% |
612,682
+2,018
| +0.3% | +$55.9K |
|
|
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $18.6M | 2.17% |
294,316
+283,016
| +2,505% | +$19.4M |
|
19
Ultragenyx Pharmaceutical
RARE
$2.45B
| $18.5M | 2.16% |
236,958
-105,645
| -31% | -$6.99M |
|
20
Zymeworks
ZYME
$1.61B
| $17.2M | 2% |
476,690
+331,781
| +229% | +$12.2M |
|
|
ARNA
21
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $16.7M | 1.94% |
265,090
+171,761
| +184% | +$9.45M |
|
|
XENT
22
DELISTED
Intersect ENT, Inc
XENT
| $16.1M | 1.87% |
1,187,450
-266,279
| -18% | -$3.1M |
|
23
United Therapeutics
UTHR
$25.8B
| $15.5M | 1.81% |
128,138
-371
| -0.3% | -$41.7K |
|
24
Codexis
CDXS
$151M
| $13.3M | 1.55% |
1,168,022
-318,576
| -21% | -$3.6M |
|
25
BioMarin Pharmaceuticals
BMRN
$11.6B
| $12.7M | 1.48% |
103,310
-1,847
| -2% | -$184K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q2 2020 Portfolio in Review
As of Q2 2020, First Light Asset Management held 74 positions worth $858M, up 47% from $586M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
First Light Asset Management deployed $61M of net new capital in Q2 2020, opening 10 new positions and adding to 22 existing holdings. Its largest new stake was Y-mAbs Therapeutics: 607,621 shares worth $26.2M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Communication Services and Energy.
On the sell side, the largest reduction was Vapotherm, Inc. Common Stock, an estimated $19.5M trimmed.
- First Light Asset Management's largest Q2 2020 buy was Y-mAbs Therapeutics: 607,621 shares worth $26.2M.
- First Light Asset Management added most to Glaukos in Q2 2020, an estimated $20.9M increase.
- First Light Asset Management's biggest Q2 2020 reduction was Vapotherm, Inc. Common Stock, cutting an estimated $19.5M.
- First Light Asset Management fully exited Iovance Biotherapeutics in Q2 2020, selling an estimated $15.9M.
- First Light Asset Management's ten largest holdings make up 51% of its $858M portfolio in Q2 2020.
- First Light Asset Management opened 10 new positions and closed 14 in Q2 2020.
- First Light Asset Management's portfolio value rose 47% quarter-over-quarter to $858M.
Based on First Light Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.